US 11,730,732 B2
Oral suspension of temozolomide
Maxime Annereau, Vincennes (FR); Jérémy Bastid, Tassin La Demi Lune (FR); Hugues Bienayme, Saint-Symphorien-d'Ozon (FR); François Lemare, Suresnes (FR); Mathieu Schmitt, Paris (FR); Lionel Tortolano, Paris (FR); and Samuel Abbou, Paris (FR)
Assigned to Orphelia Pharma, Paris (FR); and Institut Gustave Roussy, Villejuif (FR)
Filed by Orphelia Pharma, Paris (FR); and Institut Gustave Roussy, Villejuif (FR)
Filed on Dec. 13, 2019, as Appl. No. 16/713,096.
Claims priority of application No. 18306683 (EP), filed on Dec. 13, 2018.
Prior Publication US 2020/0188390 A1, Jun. 18, 2020
Int. Cl. A61K 31/495 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61K 47/40 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/495 (2013.01) [A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01); A61K 9/0053 (2013.01)] 16 Claims
 
1. A pharmaceutical composition in the form of an aqueous suspension comprising:
a. temozolomide or a salt thereof;
b. at least one agent controlling the solid state of temozolomide in the suspension;
c. water; and
d. optionally at least one acid in a quantity so that the pH of the composition is below 5;
wherein:
a concentration of temozolomide is higher than 10 mg/ml; and
the agent controlling the solid state of temozolomide in the suspension is a compound selected from the group consisting of silica (silicon dioxide), colloidal silica, hydrophobic colloidal silica, fumed silica, and mesoporous silica,
and wherein an amount of said agent controlling the solid state of temozolomide in the suspension is between 0.05 and 10% w/v of the composition.